Merck (MRK) Exchange Rate Effect (2009 - 2026)
Merck (MRK) posted quarterly Exchange Rate Effect of -$19.0 million for Q1 2026, down 112.18% year-over-year from $156.0 million in Q1 2025, and down 182.61% quarter-over-quarter from $23.0 million in Q4 2025.
Merck (MRK) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Exchange Rate Effect for 18 consecutive years, with -$19.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect fell 112.18% year-over-year to -$19.0 million; the TTM figure through Mar 2026 stood at $388.0 million (up 38700.0% YoY), while the FY2025 annual figure was $563.0 million, up 292.15% from the prior year.
- Exchange Rate Effect retreated to -$19.0 million in Q1 2026 per MRK's latest filing, from $23.0 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $374.0 million in Q2 2025 and bottomed at -$412.0 million in Q3 2022.
- Historically, Exchange Rate Effect has averaged -$8.0 million across 5 years, with a median of -$19.0 million in 2026.
- On a YoY basis, Exchange Rate Effect climbed as much as 638.24% in 2022 and fell as far as 795.65% in 2022.
- Merck's Exchange Rate Effect stood at $366.0 million in 2022, then tumbled by 49.18% to $186.0 million in 2023, then tumbled by 297.31% to -$367.0 million in 2024, then surged by 106.27% to $23.0 million in 2025, then sank by 182.61% to -$19.0 million in 2026.
- Business Quant data shows MRK's Exchange Rate Effect at -$19.0 million in Q1 2026, $23.0 million in Q4 2025, and $10.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn | 5.00 Mn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn | -7.00 Mn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn | -37.00 Mn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn | -18.00 Mn |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn | 9.00 Mn |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | -19.00 Mn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn | -4.00 Mn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.97 Bn | 47.59 Bn | 10.79 Bn | 11.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.00 Mn |
| Jun 30, 2026 | -37.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Mar 31, 2026 | -19.00 Mn |
| Dec 31, 2025 | 23.00 Mn |
| Dec 31, 2025 | 23.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Sep 30, 2025 | 10.00 Mn |
| Jun 30, 2025 | 374.00 Mn |
| Jun 30, 2025 | 374.00 Mn |
| Mar 31, 2025 | 156.00 Mn |
| Mar 31, 2025 | 156.00 Mn |
| Dec 31, 2024 | -367.00 Mn |
| Dec 31, 2024 | -367.00 Mn |
| Sep 30, 2024 | 294.00 Mn |
| Sep 30, 2024 | 294.00 Mn |
| Jun 30, 2024 | -82.00 Mn |
| Jun 30, 2024 | -82.00 Mn |
| Mar 31, 2024 | -138.00 Mn |
| Mar 31, 2024 | -138.00 Mn |